Clinical trial · Observational
Collection of Biological Samples From Patients With Rare Neurological Diseases
Prospective Collection of Biological Samples From Patients With Rare Neurological Diseases
NCT04698421CI-TRIAL-00105975EXPLAINEURrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this project is to improve biological collections of patients presenting rare neurological disorders with known or suspected autoimmune origin. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nervous System Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood collection on admission and longitudinally | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- patients with rare autoimmune neurological diseases
- interventionNames
- Biological: Blood collection on admission and longitudinally
Primary outcomes (1)
- measure
- Building a collection of biological samples and clinical-biological data from patients with rare autoimmune neurological diseases
- timeFrame
- Day 0 and through study completion, an average of 1 year
- description
- Blood sampling
Secondary outcomes (3)
- measure
- Identification of new autoantibodies.
- timeFrame
- Day 0 and through study completion, an average of 1 year
- description
- ELISA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * all patients with neurological disorders, with known or probable autoimmune involvement. This includes adults and children and peripheral and/or central nervous system symptoms. * Social coverage up to date. Exclusion Criteria: * Patients with neurological damage from which the autoimmune character can be excluded. * Known anemia and hemoglobin \<10 g / dl * Patients under protective supervision (guardianship, curators) * Pregnant or breastfeeding woman
References
Publications (0)
Data not yet available
No reference posted for this study.